🇯🇵 H5G1.1 in Japan

PMDA authorised H5G1.1 on 16 April 2010

Marketing authorisation

PMDA — authorised 16 April 2010

  • Marketing authorisation holder: Alexion Pharma
  • Status: approved

H5G1.1 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in Japan

Frequently asked questions

Is H5G1.1 approved in Japan?

Yes. PMDA authorised it on 16 April 2010.

Who is the marketing authorisation holder for H5G1.1 in Japan?

Alexion Pharma holds the Japanese marketing authorisation.